PubMed Health⌕ Search

Biomedical subjects

S A Tiuliandin

Publications and source records attributed to S A Tiuliandin.

At least 19 recordsLinked to original sources
PubMed2005

[Range of combined treatment of locally advanced skin cancer].

Due to combined use of surgery, chemo- and radiotherapy, 58.8% of patients with locally advanced squamous cell carcinoma survived for 5 years. More organ-saving operations could be performed as a result of administering cisplatin, bleomycin and 5-fluorouracil chemotherapy in conjunction with radiation and subsequent surgery. Greater extent of tumor excision and microsurgery involved lower incidence of relapse. Yet, the preliminary results of our combined treatment pointed to relatively high frequency of objective response matched by lower incidence of relapse which calls for further investigation.

Age Distribution↗
PubMed1996

[High-dose ifosfamide in the treatment of patients with soft tissue sarcoma].

The increasing doses of 2.4-3.5 g/m2 ifosfamide, i/v, dropwise, were administered for 40 min, on days 1-5 each week, for 3 weeks, in 4 courses. Simultaneously, MESNA was given in a dose two-thirds of that of ifosfamide. The maximum single tolerable dose of ifosfamide was 3.2 g/m2. The dose of 3.5 g/m2 proved neurotoxic causing encephalopathy. The other toxic effects were stage III-IV neutropenia (47%), nausea and vomiting (91%) and weakness (33%). No clinical evidence of renal failure was attributed to the high dosage of the drug in the course of assays of biochemical components of the blood, blood- and urine-beta-2-microglobulins, N-acetyl-D-hexoaminidase (NAG) level in urine, creatinine clearance and complex renoscintigraphy data. On days 3-5, ifosfamide treatment was followed by increase in NAG and beta-2-microglobulin levels in urine which pointed to the toxic effect exerted on the epithelium of renal tubules. The antitumor effect was apparent in 5 (29%) patients for 6 months, which testifies to the high effectiveness of ifosfamide treatment for soft-tissue sarcoma.

Adult↗
PubMed1995

[Germ cell tumors of the testis: current status and future progress].

The treatment of testicular cancer has undergone considerable evolution since the introduction of cisplatin and widespread recognition of its curative potentials at any stages of disease. This article provides an overview on statistical and epidemiological information, the latest developments in testicular cancer biology. Also, the results of treating 360 patients with nonseminomatous and 97 patients with seminomatous germ cell tumors are presented. A combined chemotherapy with cisplatin, etoposide and bleomycin demonstrates the highest rate of activity in nonseminomatous germ cell tumor patients. Surgical resection of residual masses after chemotherapy continues to be an important component of combined modality therapy in nonseminomatous testicular tumors. The needs for regular clinical examination during a follow-up have been underlined.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1990

[Results of chemotherapy in patients with disseminated testicular tumors].

Results of treatment of 44 patients with disseminated non-seminomatous testicular tumors versus advancement are discussed in the paper. In cases of minimal and moderate advancement (group 1), induction chemotherapy included three cycles of VAB-6 regimen (vinblastine, actinomycin D, bleomycetin, cyclophosphamide plus 120 mg/m2 platidiam) whereas cases of advanced tumor (group 2) received six such cycles; two of them used 150 mg/m2 platidiam dropwise in a 3% sodium chloride solution. Complete regression was observed in 22 of 24 (96.1%) patients of group 1 and in seven out of 20 (35%) cases of group 2; it was registered in 100, 81.8 and 38% of patients with minimal, moderately- and far-advanced disease, respectively. Patients were followed for 4-23 months (average 14.5 months). Eight cases relapsed. At the time of this writing, 38 out of 44 (86.3%) patients are alive, and 23 out of 29 (79.3%) continue in complete remission. Toxicity was moderate. Application of 3% NaCl prevented nephrotoxicity of high-dose (150 mg/m2) platidiam.

Adolescent↗
PubMed1990

[Infusion of high doses of platidiam in the treatment of patients with germ cell testicular tumors].

Sixteen patients with metastases of germ cell tumours were given VAB-6 combination chemotherapy including vinblastine, actinomycin-D, cyclophosphamide, bleomycin and platidiam (cis-platin). To intensify treatment 150 mg/m2 platidiam was administered by 24--hour infusion. Complete remission was observed in eight (50%) patients after chemotherapy alone; additional three (18.8%) cases were rendered tumor--free by surgery. At 20-26 months posttreatment, two cases were in relapse, and ten patients were alive. Toxicity was moderate. Infusion of high-dose platidiam assures a high complete remission rate, particularly, in cases of advanced germ cell tumours.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

[The results of the use of bleomycin and its analogs in the VAB-6 protocol in treating testicular tumors].

Efficacy and toxicity of VAB-6 combinations with bleomycin, bleomycetin or peplomycin were studied in treatment of 77 patients with metastases of germ-cell tumors: testicle tumors in 71 patients and extragonadal tumors in 6 patients. After the chemotherapy complete regression was observed in 37 patients (48.7 per cent). In 44 patients (57.1 per cent) residual metastases after the chemotherapy were resected. The frequency of complete regression after using the VAB-6 combinations with bleomycin, bleomycetin and peplomycin amounted to 58.8, 61.5 and 47.1 per cent respectively. The treatment results depended on the disease extent. When the disease extent was minimal complete regression was observed in 87.5 per cent of the patients. The respective figures for the disease moderate and significant extents were 66.7 and 37.8 per cent. During the average observation period of 22.1 months (7-40 months) 39 patients survived and had no signs of the disease. The combinations markedly differed in their toxicity.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

[Management and drug therapy of patients with disseminated testicular tumors].

The experience gained in the treatment of 111 cases of testicular tumor is summarized in the paper. Methods of management of testicular cancer in the eighties differ significantly from those employed in the seventies. A set of drugs used is different. The share of cases of monochemotherapy has decreased markedly. PVB and VAB-6 schemes are highly effective inducing complete or partial remission in 80-90% of cases. Issues of treatment of patients with massive metastases in retroperitoneal lymph nodes and lungs remain unresolved. Timely diagnosis of dissemination will improve chemotherapy results.

Adult↗
PubMed1984

[Use of bleomycetin in malignant testicular tumors and the problem of studying bleomycin analogs].

The efficacy of the chemotherapy of 16 patients with metastases of malignant tumors of the testicle was studied. The chemotherapy included vinblastine, platidiam and bleomycetin. The latter was used in a dose of 10 mg daily intramuscularly or as long-term intravenous infusions. As a result of the treatment complete and partial regression of the tumors was observed in 5 (31 per cent) and 4 (25 per cent) patients, respectively. Leukopenia was the main side effect. By present the total doses of bleomycetin had amounted to 250 mg for 4 patients and to 300-350 mg for 7 patients. No signs of pulmonary toxicity were observed with the use of these doses. The problem of clinical studies of bleomycin analogs is discussed.

Antibiotics, Antineoplastic↗